Intrinsiqq
Alumis Inc. logo

Alumis Inc. Financials

ALMS

⊜ Compare

All currency values in $ millions unless otherwise noted

Income Statement
TTM
~1.5:1 split
DEC 2025
3:1 split
DEC 2024
~13.2:1 split
DEC 2023
Revenues
Revenue$7$24––
General & Administrative$77$92$35$20
Research & Development$347$386$266$138
Total Operating Expenses$466$478$301$158
Operating Income-$459-$454-$301-$158
Other Non-Operating Income (Expense)$18$202$7$3
EBT (Earnings Before Tax)–-$252-$294–
Income Tax Expense–-$9$0$0
Net Income
Net Income-$439-$243-$294-$155
Per Share Data
Revenue Per Share$0.06$0.28––
EPS (Basic)-$3.67-$2.86-$10.38-$72.08
EPS (Diluted)-$3.66-$2.86-$10.38-$72.08
Weighted Avg Shares (Basic)127.7M85.0M28.3M2.2M
Weighted Avg Shares (Diluted)127.7M85.0M28.3M2.2M
Shares Outstanding127.7M85.0M28.3M2.2M

Alumis (ALMS) financials: revenue, profit and margins

Alumis (ALMS) generated about $7 million in revenue and -$439 million in net income (a -5,933.5% net margin) over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Alumis's (ALMS) revenue?+

Alumis generated about $7 million in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Alumis profitable?+

Alumis reported about -$439 million in net loss over the trailing twelve months, a net margin of roughly -5,933.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Alumis's profit margins?+

Alumis runs an operating margin of about -6,204.4%, a net margin of about -5,933.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ALMS

CompareIntrinsic value
ROIVRoivant Sciences Ltd
$38.23+6.08%16
ADAGAdagene Inc.
$2.41+2.55%25
OVIDOvid Therapeutics Inc.
$2.74+14.17%25
NAMSNewAmsterdam Pharma Co. N.V.
$20.93+5.18%10
COYACoya Therapeutics Inc.
$3.08-0.96%10
ACRSAclaris Therapeutics, Inc.
$3.68-1.60%10
HCWBHCW Biologics Inc.
$1.08-6.09%15
ABEOAbeona Therapeutics Inc.
$4.22-0.71%40

Held by ETFs

ALMS is in 36 US ETFs. The largest of them, with ALMS's weight in each:

Spot a number that looks wrong? Check it in ALMS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ALMS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.